Tim Yoon, CEO
Tim Yoon has 5 doctors in his family, went from 252 to 155 lbs, and studied to become a doctor during high school. Being raised in a health-oriented family that has gone through many illnesses built a passion toward healthcare.
The biggest opportunity in the peptide industry is data.
Data produces new research. New research creates peptide safety, efficacy, and quality.
Peptide safety, efficacy, and quality converts millions of prior non believers. Converted non believers expand the market.
Market expansion creates the greatest value.
Tempus for peptides
Peptide AI connects clinic data to research intelligence.
Tempus AI is a $10B data company for cancer. Their product supports researchers in developing novel cancer drugs.
Peptide AI is the same connective tissue for peptides: patient data, prescribing workflows, and researcher-grade insight in one market-expanding loop.
Why Now?
The market is moving now
$556B in out-of-pocket healthcare spent in 2024 proves consumers are demanding proactive over reactive healthcare, which is exactly the use case for peptides.
July 23rd's PCAC meeting could push billions of peptide volume from gray-market demand into clinics, the exact market Peptide AI Rx serves.
AI can identify correlations across infinite data points that were previously impossible with simple boolean logic, which is the core technology Peptide AI Insights is built on.
Peptide AI Rx (Problem Solution)
The e-prescription platform for peptides.
Clinics need reliable sourcing and prescribing support. They are juggling multiple compounders while clinicians decide protocols without enough peptide-specific training.
- A marketplace aggregates compounder supply and clinic demand into one e-prescription platform.
- An AI agent recommends peptide protocols from individualized patient data, then routes the order through the right supply path.
That workflow is how Peptide AI captures consented, de-identified, HIPAA-compliant patient data while helping clinics move faster.
Peptide AI Insights (Problem Solution)
Regulatory-grade answers in seconds.
RWE and HEOR researchers need proof that GLP-1s and peptide protocols save costs, expand labels, and de-risk trials. Anecdotes are not enough.
- Peptide patients' real outcomes, exact dosing and titrations, labs, biomarkers, side effects, and adherence over time.
- Consent-based, de-identified, HIPAA-compliant data built to standards real-world evidence teams can take to payers and regulators.
- An intelligence layer that turns raw data into payer dossiers, label-expansion support, and responder-population insight.
Our Team
Why this team can capture the peptide network.
Dawson Cesarek, CTO
Dawson Cesarek grew up around healthcare through both of his parents, who are nurses. He has built software across web platforms, infrastructure, automation, and scalable systems for real-world business use.
Karthik Achari, Head of Network
Karthik Achari has built DNA Corp, a lab testing company for hospital systems, Pure Rx, a peptide infrastructure business, and Pep MD, a certification body for the peptide industry.
Risks
Where Peptide AI may fail
These are the highest-leverage risks to solve before the network compounds.
Some clinics will opt out. But clinics benefit when the peptide market grows, and Peptide AI can frame consented data sharing around safety, efficacy, quality, and market expansion.
Some research outcomes support insurance pharma more than cashpay clinics. Published research still moves the industry forward, and a larger peptide market benefits the cashpay ecosystem.
It is a weakness and a strength. Outsiders throw out inherited assumptions. Tim's distribution background matters in a network effects business where speed and virality can compress enterprise cycles.
Powers
Network Effects
We build network effects between clinics and compounders through Rx and between patients and pharma through Insights.
Capital Moats
We start with cash flow from e-prescribing, then compound it through data licensing and recurring software revenue.
Switching Costs
Clinics, compounders, and pharma teams all build workflows on top of Peptide AI's data and operating layer.
Budget Capture
We capture IT budgets and labor budgets by saving clinics and compounders time across sourcing, prescribing, and sales operations.
Now What?
The mission is simple: use peptides as the wedge to make healthcare more proactive, more evidenced, and more useful for the people already paying out of pocket for better health.
DM Tim Yoon on LinkedIn